FATE THERAPEUTICS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M |
| Operating income | -$147.7M | -$210.3M | -$190.5M | -$308.4M | -$217.0M |
| Operating expenses | $154.3M | $223.9M | $254.0M | $404.7M | $272.8M |
| Cash from operations | -$106.1M | -$122.9M | -$132.3M | -$248.2M | -$162.9M |
| Capital expenditure | $6.0M | $730,000 | $6.2M | $35.6M | $50.7M |
| Free cash flow | -$112.0M | -$123.6M | -$138.4M | -$283.8M | -$213.6M |
| Impairments | $0 | $13.4M | $0 | — | — |
| Total assets | $318.9M | $440.7M | $506.2M | $705.6M | $921.5M |
Shares outstanding 116.6M · Free float 81.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.